Pharmacogenetic Tests in Asthma Therapy

Clinics in Laboratory Medicine

Volumn 28, Issue 4, 2008, Pages 645-665

  Yu, I Wen ^a   Bukaveckas, Bonny Lewis ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCUNEB; ARFORMOTEROL; ARGININE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; GLYCINE; LEVALBUTEROL; ORCIPRENALINE; PIRBUTEROL; PIRBUTEROL ACETATE; PROCATEROL; PROVENTIL HFA; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; UNCLASSIFIED DRUG; VOSPIRE ER;

AMINO ACID SUBSTITUTION; ASTHMA; CAUCASIAN; CLINICAL ASSESSMENT; DISEASE EXACERBATION; DRUG METABOLISM; ETHNICITY; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; LONG TERM CARE; LUNG FUNCTION; MORTALITY; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTI-ASTHMATIC AGENTS; ASTHMA; FEMALE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RECEPTORS, ADRENERGIC, BETA-2;

EID: 57049174625     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2008.05.001     Document Type: Review

References (48)

1. "10 Facts on asthma" World Health Organization fact file. Available at:. http://www.who.int/features/factfiles/asthma/en/index.html [Accessed on March 14, 2008]
2. Lugogo N.L., and Kraft M. Epidemiology of asthma. Clin Chest Med 27 1 (2006) 1-15 v
3. National Surveillance for Asthma-United States, 1980-2004. CDC report. Available at:. http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5608a1.htm [Accessed on March 5, 2008]
4. Centers for Disease Control and Prevention. Asthma prevalence and control characteristics by race/ethnicity-United States, 2002. MMWR Morb Mortal Wkly Rep 53 (2004) 145-148
5. Cost of asthma. Available at:. http://www.aafa.org/display.cfm?id=6&;sub=63&cont=252 [Accessed on March 5, 2008]
6. Kelly W.H., and Sorkness C.A. Asthma. In: Dipiro J.T., Talbert R.L., Yee G.C., et al. (Eds). Pharmacotherapy: a pathophysiologic approach. 5th edition (2002), McGraw Hill, New York 475-510
7. National Asthma Education and Prevention Program Expert Panel. Expert panel report 2: guidelines for the diagnosis and management of asthma. National Institute of Health Publication, Publication Number 97-4051, Bethesda, MD, 1997. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf [Accessed on March 5, 2008]
8. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 58 Suppl 1 (2003) i1-94
9. Mohamed M.H., Lima J.J., Eberle L.V., et al. Effects of gender and race on albuterol pharmacokinetics. Pharmacotherapy 19 (1999) 157-161
10. Serevent Diskus prescribing information. Available at:. http://us.gsk.com/products/assets/us_serevent_diskus.pdf [Accessed on March 5, 2008]
11. Whelna G.J., and Szefler S.J. Asthma management. In: Burton M.E., Shaw L.M., Schentag J.J., and Evans W.E. (Eds). Applied pharmacokinetics & pharmacodynamics principles of therapeutic drug monitoring. 4th edition (2006), Lippincott Williams & Wilkins, Baltimore, MD 259-283
12. Taylor D.R., Sears M.R., and Cockcroft D.W. The beta-agonist controversy. Med Clin North Am 80 (1996) 719-748
13. Martinez F.D., Graves P.E., Baldini M., et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100 (1997) 3184-3188
14. Hankinson J., Odencrantz J., and Fedan K.B. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 159 1 (1999) 179-187
15. Chervinsky P., van As A., Bronsky E.A., et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. J Allergy Clin Immunol 94 4 (1994) 676-683
16. Szefler S.J., Martin R.J., King T.S., et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109 (2002) 410-418
17. Kharitonov S.A., Yates D., Robbins R.A., et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343 (1994) 133-135
18. Smith A.D., Cowan J.O., Brassett K.P., et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 172 (2005) 453-459
19. Zhang J., Yu C., Holgate S.T., et al. Variability and lack of predictive ability of asthma end-points in clinical trials. Eur Respir J 20 (2002) 1102-1109
20. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 170 (2004) 836-844
21. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 140 10 (2004) 802-813
22. Crane J., Pearce N., Flatt A., et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1 (1989) 917-922
23. Spitzer W.O., Suissa S., Ernst P., et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326 (1992) 501-506
24. Suissa S., Ernst P., Boivin J.F., et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 149 (1994) 604-610
25. Taylor D.R., Sears M.R., Herbison G.P., et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 48 (1993) 134-138
26. van Schayck C.P., Cloosterman S.G., Bijl-Hofland I.D., et al. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists. Respir Med 96 (2002) 155-162
27. Nelson H.S., Weiss S.T., Bleecker E.R., et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
28. Salpeter S.R., Buckley N.S., Ormiston T.M., et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
29. Drazen J.M., Silverman E.K., Lee T.H., et al. Heterogeneity of therapeutic responses in asthma. Br Med Bull 56 (2000) 1054-1070
30. Kobilka B.K., Kobilka T.S., Daniel K., et al. Chimeric alpha 2-, beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science 240 4857 (1988) 1310-1316
31. Johnson M. Molecular mechanisms of beta(2)-beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 117 (2006) 18-24 quiz 25
32. Kobilka B.K., MacGregor C., Daniel K., et al. Functional activity and regulation of human beta 2-adrenergic receptors expressed in Xenopus oocytes. J Biol Chem 262 32 (1987) 15796-15802
33. Hawkins G.A., Tantisira K., Meyers D.A., et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 174 (2006) 1101-1109
34. NCBI dbSNP. SNP linked to Gene ADRB2 (geneID:154) Via Contig Annotation Available at:. http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=154 [Accessed on March 5, 2008]
35. Israel E., Drazen J.M., Liggett S.B., et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162 (2000) 75-80
36. Reihsaus E., Innis M., MacIntyre N., et al. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 8 (1993) 334-339
37. McGraw D.W., Forbes S.L., Kramer L.A., et al. Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 102 (1998) 1927-1932
38. Drysdale C.M., McGraw D.W., Stack C.B., et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 97 (2000) 10483-10488
39. HapMap data Rel22. Available at:. http://www.hapmap.org/cgi-perl/gbrowse/hapmap_B36/ [Accessed on March 5, 2008]
40. Maxwell T.J., Ameyaw M.M., Pritchard S., et al. Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. Int J Mol Med 16 (2005) 573-580
41. Green S.A., Turki J., Innis M., et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33 (1994) 9414-9419
42. Green S.A., Turki J., Bejarano P., et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 13 (1995) 25-33
43. Choudhry S., Ung N., Avila P.C., et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 171 (2005) 563-570
44. *. Pharmacogenomics 6 (2005) 399-410
45. Tsai H.J., Shaikh N., Kho J.Y., et al. Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet 119 (2006) 547-557
46. Small K.M., McGraw D.W., and Liggett S.B. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43 (2003) 381-411
47. Taylor D.R., Drazen J.M., Herbison G.P., et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 55 (2000) 762-767
48. Wechsler M.E., Lehman E., Lazarus S.C., et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173 (2006) 519-526